Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
- Conditions
- Lymphoma, T-Cell
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06699771
- Locations
- 🇰🇷
Seoul National University Hosptial, Seoul, Korea, Republic of
🇰🇷Seoul National University Hosptial, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 230
- Registration Number
- NCT06620510
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
- Conditions
- Breast CancerGastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06341647
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺The Alfred Hosptial, Melbourne, Victoria, Australia
🇦🇺Austin Hosptial, Melbourne, Victoria, Australia
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Genetic: CT303
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05258331
- Locations
- 🇰🇷
CHA Medical School Bundang CHA Medical Center, Gyeonggi-do, Korea, Republic of
🇰🇷Pusan national university hospital, Pusan, Korea, Republic of
🇰🇷Seoul national university hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Genetic: CT303
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- GC Cell Corporation
- Registration Number
- NCT05238532
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
🇰🇷Seoul national university boramae medical center, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seoul, Korea, Republic of
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 408
- Registration Number
- NCT04969731
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Daehak-ro, Jongno-gu, Korea, Republic of
Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation
- Conditions
- Liver Transplantation
- Interventions
- Biological: Immuncell-LC
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 19
- Registration Number
- NCT03983967
- Locations
- 🇰🇷
Seoul National Hospital, Seoul, Korea, Republic of
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
- Conditions
- Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
- Interventions
- Biological: MG4101(allogeneic Natural Killer cell)
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03778619
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National Univ. Hospital, Seoul, Korea, Republic of
Safety and Efficacy of "Immuncell-LC" in TACE Therapy
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Biological: Immuncell-LC
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT02856815
- Locations
- 🇰🇷
Seoul St.Mary's Hospital, Seoul, Banpo-daero 222 / Seocho-go, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Daehak-ro 101/Jongno-gu, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Seoul,50-1 Yonsei-ro/Seodaemun-gu, Korea, Republic of
A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: MG4101
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 78
- Registration Number
- NCT02854839
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul Asan Medical center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of